Effect of bimatoprost sustained-release intracameral implant on intraocular pressure and medication burden in patients with prior glaucoma surgery
Authors:
- 3 November 2023
- journal article
- research article
- Published by Elsevier in Journal Français d'Ophtalmologie
- Vol. 47 (2) , 103996
Abstract
No abstract availableKeywords
Funding Information
- Allergan
This publication has 15 references indexed in Scilit:
- 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma PatientsDrugs, 2019
- Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target TissuesJournal of Ocular Pharmacology and Therapeutics, 2019
- The Most Common Barriers to Glaucoma Medication AdherenceOphthalmology, 2015
- The Pathophysiology and Treatment of GlaucomaJAMA, 2014
- Effects of Common Topical Antiglaucoma Medications on the Ocular Surface, Eyelids and Periorbital TissueDrugs & Aging, 2011
- Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular HypertensionAmerican Journal of Ophthalmology, 2010
- Side Effects Associated with Prostaglandin Analog TherapySurvey of Ophthalmology, 2008
- Noncompliance with Ocular Hypotensive Treatment in Patients with Glaucoma or Ocular HypertensionAn Evidence-Based ReviewOphthalmology, 2005
- Comparison of the Short-Term Effects on the Human Corneal Surface of Topical Timolol Maleate With and Without Benzalkonium ChlorideJournal of Glaucoma, 2003
- Reduction of Intraocular Pressure and Glaucoma ProgressionArchives of Ophthalmology (1950), 2002